Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRC-063 in Adolescent ADHD
NCT02139111Phase 3Completed
- Sponsor
- Rhodes Pharmaceuticals
- Start
- Apr 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of methylphenidate osmotic release oral system in attention deficit hyperactivity disorder (ADHD), sponsored by Rhodes Pharmaceuticals. Started Apr 2014; status: completed.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02139111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02139111.